Podoplanin Expression in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma

Overview

Journal J Clin Exp Dent

Specialty Dentistry

Date 2018 Feb 8

PMID 29410757

Citations 7

Authors

Deepa A G

Bindu Janardanan-Nair

Varun B R

Affiliations

Soon will be listed here.

Abstract

Background: Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podoplanin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal mucosa by immunohistochemical methods.

Material And Methods: Immunohistochemical expression of podoplanin was analyzed in 20 cases each of oral leukoplakia, oral submucous fibrosis, oral squamous cell carcinoma and normal buccal mucosa, with monoclonal antibody D2-40. The expression of podoplanin was graded from grade 0-4.

Results: There was a statistically significant upregulation of the grades of podoplanin expression in oral squamous cell carcinoma(100%), oral submucous fibrosis (90%) and oral leukoplakia (65%) when compared to that in normal mucosa(35%). Podoplanin expression increased with decrease in grades of differentiation in oral squamous cell carcinoma . Podoplanin expression in the samples of oral submucous fibrosis was higher than that in oral leukoplakia.

Conclusions: Evaluation of podoplanin expression in the epithelial cells of oral dysplastic lesions may provide valuable information to predict their risk of malignant transformation. Immunohistochemistry, Oral leukoplakia, Oral submucous fibrosis, Podoplanin, Squamous cell carcinoma.

Citing Articles

Podoplanin expression in various types of oral dysplasia and oral squamous cell carcinoma.

Mashhadiabbas F, Chafjiri M, Dashti M, Mudasser M, Gholami S J Taibah Univ Med Sci. 2025; 20(1):40-51.

PMID: 39866370 PMC: 11761884. DOI: 10.1016/j.jtumed.2024.11.007.

Evaluation of immuno-histochemical markers in oral squamous cell carcinoma.

Guruprasad Y, Singhal P, Gupta N, Kukreja B, Gupta B, Kukreja P Bioinformation. 2024; 19(13):1399-1404.

PMID: 38415034 PMC: 10895524. DOI: 10.6026/973206300191399.

A Comparison of Podoplanin Expression in Oral Leukoplakia and Oral Squamous Cell Carcinoma: An Immunohistochemical Study.

Srinivasan V, Shyam N, Kiran Kumar G, Narayen V, Konda P, Swetha Rani K Cureus. 2023; 15(5):e38467.

PMID: 37273383 PMC: 10238285. DOI: 10.7759/cureus.38467.

Lymphatic Vascular Density, the Expression of Podoplanin and Tumor Budding in Oral Squamous Cell Carcinoma.

de Assis E, Rodrigues M, Vieira J, Pascoaloti M, Junior H, Souto G Head Neck Pathol. 2022; 17(2):371-382.

PMID: 36480090 PMC: 10293516. DOI: 10.1007/s12105-022-01511-z.

Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts as a Potential Biomarker of Malignant Transformation in Oral Leukoplakia.

Monteiro L, do Amaral B, Delgado L, Garces F, Salazar F, Pacheco J Biomolecules. 2022; 12(5).

PMID: 35625534 PMC: 9138639. DOI: 10.3390/biom12050606.

References

Margaritescu C, Raica M, Pirici D, Simionescu C, Mogoanta L, Stinga A . Podoplanin expression in tumor-free resection margins of oral squamous cell carcinomas: an immunohistochemical and fractal analysis study. Histol Histopathol. 2010; 25(6):701-11. DOI: 10.14670/HH-25.701. View

Franchi A, Gallo O, Massi D, Baroni G, Santucci M . Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer. 2004; 101(5):973-8. DOI: 10.1002/cncr.20454. View

Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y . Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol. 2011; 33(1):183-94. DOI: 10.1007/s13277-011-0261-7. View

Huber G, Fritzsche F, Zullig L, Storz M, Graf N, Haerle S . Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2010; 129(6):1404-9. DOI: 10.1002/ijc.25795. View

Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M . Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology. 2011; 78(3):171-80. DOI: 10.1159/000324926. View

Raica M, Cimpean A, Ribatti D . The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008; 28(5B):2997-3006. View

Warnakulasuriya S . Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol. 2010; 46(6):407-10. DOI: 10.1016/j.oraloncology.2010.02.015. View

Akinyamoju A, Adeyemi B, Kolude B, Adisa A . Histological grading of oral squamous cell carcinoma patients in Ibadan using Bryne's and Broders' grading systems--a comparative study. Afr J Med Med Sci. 2014; 42(4):333-7. View

PINDBORG J, SIRSAT S . Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966; 22(6):764-79. DOI: 10.1016/0030-4220(66)90367-7. View

10.

Patil A, Patil K, Tupsakhare S, Gabhane M, Sonune S, Kandalgaonkar S . Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma. Scientifica (Cairo). 2015; 2015:135298. PMC: 4618324. DOI: 10.1155/2015/135298. View

11.

Kreppel M, Kreppel B, Drebber U, Wedemayer I, Rothamel D, Zoller J . Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis. 2012; 18(7):692-9. DOI: 10.1111/j.1601-0825.2012.01927.x. View

12.

Yuan P, Temam S, El-Naggar A, Zhou X, Liu D, Lee J . Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006; 107(3):563-9. DOI: 10.1002/cncr.22061. View

13.

Miyazaki Y, Okamoto E, Gonzalez-Alva P, Hayashi J, Ishige T, Kikuchi K . The significance of podoplanin expression in human inflamed gingiva. J Oral Sci. 2009; 51(2):283-7. DOI: 10.2334/josnusd.51.283. View

14.

Silverman S, Bhargava K, Smith L, MALAOWALLA A . Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer. 1976; 38(4):1790-5. DOI: 10.1002/1097-0142(197610)38:4<1790::aid-cncr2820380456>3.0.co;2-i. View

15.

Reibel J . Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003; 14(1):47-62. DOI: 10.1177/154411130301400105. View

16.

Holmstrup P, Vedtofte P, Reibel J, Stoltze K . Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2005; 42(5):461-74. DOI: 10.1016/j.oraloncology.2005.08.011. View

17.

Abbey L, Kaugars G, Gunsolley J, Burns J, Page D, Svirsky J . Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 80(2):188-91. DOI: 10.1016/s1079-2104(05)80201-x. View

18.

de Vicente J, Rodrigo J, Rodriguez-Santamarta T, Lequerica-Fernandez P, Allonca E, Garcia-Pedrero J . Podoplanin expression in oral leukoplakia: tumorigenic role. Oral Oncol. 2013; 49(6):598-603. DOI: 10.1016/j.oraloncology.2013.02.008. View

19.

Silverman Jr S, Gorsky M, Lozada F . Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984; 53(3):563-8. DOI: 10.1002/1097-0142(19840201)53:3<563::aid-cncr2820530332>3.0.co;2-f. View

20.

Prasad B, Kashyap B, Babu G, Kumar G, Manyam R . Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma. Ann Med Health Sci Res. 2015; 5(4):299-304. PMC: 4512124. DOI: 10.4103/2141-9248.160181. View